83ACTIVITIES
1ORGS REPRESENTED
38BILLS
Organizations represented
1Orgs whose LD-2 filings list Phyllis as an active lobbyist, sorted by activity volume.
Bills they file on
38H.R. 126248 mentions
S. 93245 mentions
H.R. 167235 mentions
S. 86431 mentions
H.R. 616630 mentions
S. 52730 mentions
S. 52630 mentions
H.R. 642330 mentions
S. 109529 mentions
S. 109629 mentions
S. 109729 mentions
H.R. 326928 mentions
S. 227628 mentions
H.R. 648528 mentions
S. 4328 mentions
+ 23 more bills referenced in their activities
Topics in Filings
306Policy topics Phyllis files on across all their LD-2 activities.
Medical Countermeasure Priority Review Voucher Reauthorization×145
CMMI: GLOBE and GUARD Models×98
National Coverage Determination×85
R&D Funding for Medical Countermeasures×77
Lowering Drug Costs for American Families Act×77
Preserve Access to Affordable Generics and Biosimilars Act×71
Pharmacy Benefit Manager Transparency Act×70
CMMI Authority×70
International Pricing Policies×70
Prescription Pricing for the People Act×68
Antimicrobial Resistance×67
Stop STALLING Act×66
Show all 306 topics (+294 more) ▾
FY 2026 Appropriations for Specific Issues×61
Most Favored Nation Drug Pricing Proposals×57
340B Rebate Rule×56
Interagency Patent Coordination and Improvement Act×54
Maintaining Investments and New Innovation×54
Drug Supply Chain Management×51
Supply Chain Issues×51
Clinical Trial Data in China×51
Drug Pricing×50
Pandemic Preparedness×50
Development and Procurement Issues×49
Development and Procurement×49
Funding for Strategic National Stockpile×49
Vaccines and Infectious Diseases×49
FY 2026 Appropriations for Agencies×48
Centers for Disease Control and Prevention×48
Health Resources and Services Administration×48
HHS Office of Infectious Disease and HIV/AIDS Policy×48
Biodefense/Biomedical/Emergency Preparedness Research×48
Administration for Strategic Preparedness and Response×42
Biomedical Advanced Research and Development Authority×42
Pediatric Priority Review Voucher×42
Big Savings Act×42
MCM PRV Reauthorization×38
Vaccine Injury Compensation Program×37
Quality & Distribution×35
Advanced Manufacturing×35
Drug Shortages×35
Supply Chain Integrity and Traceability×35
Patient Cost-Sharing and Implementation×35
Alternative Payment Arrangements for Gene Therapies×35
Drug Benefit Design×35
National Defense Authorization Act×35
Adult Immunization×35
Vaccine Safety net and Vaccine Infrastructure×35
Value of Vaccines and Vaccine Confidence×35
Pricing and Rebates×34
MCM Manufacturing & Capacity×34
Alternative Funding Programs×34
Biosimilar Red Tape Elimination Act×34
SAFE STEP Act×34
Risky Research Review Act×33
Average Manufacturer Price Calculations×33
Support of Patient Premiums and Cost-Sharing Obligations×33
Medicare Drug Price Negotiation Act×33
Modernizing and Ensuring PBM Accountability×33
Funding for Women's Health Research×32
Medicaid VBPs for Patients×32
Orphan Drug Tax Credit×32
Let Injured Americans Be Legally Empowered×32
Vaccine Injury Compensation Modernization×32
Value-based Contracting and Communications×31
Increasing Transparency in Generic Drug Application×31
Vaccine Access Improvement Act×31
Pandemic Preparedness -R&D Funding for Medical Countermeasures×30
Non-Opioid Analgesics Orphan Drug Issues×29
Food & Drug Administration×28
National Defense Authorization Act 2027×28
Biosimilars Competition×28
Data Privacy Working Group Draft×28
CMMI×28
Pediatric Priority Review Voucher Pandemic Preparedness×28
Restrictions on Intellectual Property Rights×25
Value-Based Purchasing×23
Executive Order on Access to Affordable Life-Saving Medications×21
Strengthening Innovation in Medicare and Medicaid Act×21
Mandating Exclusive Review of Individual Treatments×21
Biosimilar Copay×20
Interchangeability and Pharmacy Substitution×20
Promising Pathway Act×20
PBM Reform×20
Medicare Part B Physician-Administered Products×20
Maternal Immunization×20
Program Implementation & Oversight×20
PROTECT 340B Act×20
CICP×19
Coverage of Accelerated Approval Products×19
Patient Cost-Sharing and Smoothing×19
SUSTAIN 340B Act×19
Prescription Drug User Fee Act×19
Affordable Prescriptions for Patients Act×19
Access to Innovative Treatments Act×19
Accelerated Approval Artificial Intelligence×18
MCM PRV Program Reauthorization×18
WHO Pandemic Preparedness Accord Biosimilars×18
Reimbursement Cell & Gene Therapy×18
COVID-19 Pricing Related Provisions×18
Countermeasures Injury Compensation Program×18
Vaccine and Antimicrobial Resistance Product Development and Incentives×18
Vaccine Safety and Quality×18
VICP Loopholes×18
Advanced Research Projects Agency for Health×17
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×17
Biosimilars Red Tape Elimination Act×17
Medicaid Drug Rebate Program×17
Influenza Planning & Response×17
Project Bioshield×17
American Privacy Rights Act×17
FDA Hiring Flexibility×17
Medication Affordability and Patient Integrity Act×17
DRUG Act×17
FDA Modernization×17
Act 3.0 Medicaid×17
Innovation in Pediatric Drugs Act×17
Retaining Access and Restoring Exclusivity×17
Step Therapy×17
MCM R&D Incentives×17
Vaccine Quality Measure×17
Vaccine Safety×17
One Big Beautiful Bill Act×17
Diversity & Inclusion×16
Compounded Medicines×16
BIOSECURE Act×16
Decentralized Clinical Trials Drug Evaluation and Review×16
Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×16
Disease X Act×16
Gain of function×16
SAFE Risky Research Act×16
Countermeasure Injury Compensation Fund Amendment Act×16
Pandemic Flu×16
Generic Drug Entry×16
Generic Drug Application Review Reforms×16
Incentives for Generic Entry Issues×16
State Strategic Stockpile Act×16
Accelerated Approval Antimicrobial Resistance Artificial Intelligence×16
House GOP RFI on Supply Chain×15
White House National Biodefense Strategy×15
Coverage and Reimbursement×15
Section 317 Immunization Program×15
Vaccine Injury Compensation Program 340B Drug Discount Program×15
Compounding Pharmacies×15
Contract Manufacturing Ecosystem in the United States×15
Access to Innovative Treatments×15
PASTEUR ACT×15
Funding for Medical Countermeasures×15
VICP/CICP Antimicrobial Resistance Biodefense Research×15
Vaccines and Infectious Diseases 340B Drug Discount Program×15
Most Favored Nation in Medicaid×15
NSCEB Recommendations Opioid Crisis×15
VICP/CICP Capital Formation Incentives×15
Cameron's Law Pandemic Preparedness Research & Development Tax Credit Reforms×15
Expensing of R&D Expenditures×15
Bio COMPETES×14
Centers for Medicare and Medicaid×14
National Institutes of Health×14
Purple Book Draft×14
Consumer Data Privacy and Security Act×14
Diagnostics and Personalized Medicine Regulation and Oversight×14
PDUFA VII Implementation×14
PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14
Biosecurity Modernization×14
NSC/OSTP priorities×14
Nucleic acid synthesis security and biotechnology governance×14
Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14
VICP/CICP Biodefense Research×14
WHO Pandemic Preparedness Accord Pandemic Preparedness×14
Funding for Section 317×14
CDC Reform×14
FDA Hiring Staffing Drug Importation Drug Manufacturing×14
Tariffs Foreign Drug Data Protection Laws Medicaid×14
American Innovation and Jobs Act×14
Incentives for Domestics Manufacturing Orphan Drug Issues×14
R&D Payroll Credit Vaccines and Infectious Disease×14
ORPHAN Cures Act×13
Monoclonal Antibody Coverage and Utilization×12
FY 2025 Appropriations×10
SUPPORT Act×7
FY 2026 Appropriations×6
Temporarily Refundable R&D Credit×6
WHO Pandemic Preparedness Accord×6
Prescription Drug Price Relief Act×6
Safe, and Secure American Bioeconomy×5
Give Kids a Chance Act×5
Pediatric Priority Review Voucher Program×5
HELP Copays Act×5
ASPR×5
Patent Thickets×4
Non-Opioid Analgesics×4
TRIPS Waiver×4
Administration Rebate Rule×4
Lower Costs×4
Protected Classes×4
Most Favored Nation×4
Fair Prescription Drug Prices for Americans Act×4
Emerging New Threats and×4
Orphan Drug Issues×4
Finding Orphan-Disease Remedies with Antifungal Research and Development×4
Reasonable Pricing Clauses in BARDA Contracts×3
Tropical Disease Priority Review Voucher×3
Decentralized Clinical Trials×3
FDA Hiring Flexibility Drug Importation Drug Manufacturing×3
Orphan Drug Tax Credit Pandemic Preparedness×3
Medical Countermeasures PRV Reauthorization×3
Global Fairness in Drug Pricing Act×3
Creating Hope Reauthorization×3
PPRV×3
340B Accountability Act×3
Bill to address patent thickets×3
Medicare Negotiation and Competitive Licensing Act×3
BARDA×3
National Defense Authorization Act 2026×3
NDAA×2
House GOP RFI on Data Privacy×2
COVID-19 Lessons Learned×2
VICP×2
Medicaid Drug Rebate Program Rule×2
Coverage and Reimbursement Orphan Drug Issues×2
More Cures Act×2
CFIUS and Foreign Investment Drug Importation Drug Pricing×2
Protecting Americans Data from Foreign Adversaries Act×2
B5 Coalition on Supply Chain Resiliency×2
Genetic Resources, and Associated Traditional Knowledge×2
BSUFA Negotiations×2
Cell & Gene Therapy×2
Compounded Medicines Drug Patenting×2
Most Favored Nation Foreign Drug Data Protection Laws×2
National Institute of Health×2
Improving Data Accessibility Through Advancements×2
Drug Evaluation and Review×2
Drug Importation Drug Manufacturing×2
Stronger Patents Act×2
Protecting Patient Access to Cancer and Therapies×2
More Transparency Act×2
Family Vaccine Protection Act×2
Gene Editing×2
MCM PRV Program×2
Executive Order on Achieving Efficiency Through State and Local Preparedness×2
HHS Reorganization×2
Foreign Drug Data Protection Laws×2
National Institutes of Health FY 2026 Appropriations for Specific Issues×2
340B Drug Discount Program×1
Program & Oversight×1
Biosecurity Infrastructure for Operational×1
American Pandemic Preparedness Plan×1
MINI Act×1
Climate Change×1
FY 2026 Appropriations Data Privacy×1
Clinical Trial Diversity Drug Evaluation and Review×1
MCM PRV×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
FY 2026 Appropriations Funding for National Institutes of Health×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
China Biotechnology Regulations×1
EU Ag-Biotech Policies×1
International Consistency of Regulation for Gene Edited Products×1
Korea Biotechnology Regulations×1
Medical Supply Chain Resiliency Act×1
Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement×1
Ag-Biotech Provisions×1
IP Provisions World Health Organization×1
WHO Pandemic Preparedness Accord World Intellectual Property Office×1
Treaty on Intellectual Property×1
Patent Thickets Drug Pricing×1
Regulatory Harmonization Medicaid×1
BARDA FY 2026 Appropriations for Specific Issues×1
Section 317 Immunization Program 340B Drug Discount Program×1
Accelerated Approval Access to non-human Primates×1
Climate Change Data Privacy×1
PDUFA×1
FDA Reform×1
Compounding & Counterfeit Medicines Drug Patenting×1
Rare Disease Pilot Program Pandemic Preparedness×1
Project Bio Shield×1
End Price Gauging for Medications Act×1
SMART Prices Act×1
VICP CICP×1
ASPR FY 2026 Appropriations for Specific Issues×1
HHS Reorganization Pandemic Preparedness×1
National Institute of Health FY 2026 Appropriations for Specific Issues×1
Reimbursement Cell & Gene Therapy Data Privacy×1
Clinical Trial Modernization×1
Drug Rebate Program Rule×1
Prescription Drug Pricing for the People Act×1
Reference Pricing in Drug Reimbursement×1
Most Favored Nation Foreign Agricultural Biotechnology Laws and Regulations×1
China Synthetic Biotech Tariffs Trade Relations×1
Section 232×1
World Intellectual Property Office×1
340B ACCESS Act×1
Synthetic Nucleic Acid Synthesis Screening×1
PDUFA VIII Negotiations×1
Drug Manufacturing×1
Biologics Competition Act×1
Enhanced Access to Affordable Medicines Act×1
Most Favored Nation Pricing Opioid Crisis×1
Reimbursement and Coverage of Innovative Products×1
Administrative Rebate Rule×1
MCM PRV Program CDC Reform×1
340B Rebate Pilot Program×1
FDA Hiring Flexibility Drug Manufacturing×1
Most Favored Nation Pricing×1
Vaccine Access×1
Vaccines for Children Program×1
Issue mix
LDA general-issue codes weighted by activity count.
Health Issues18
Medicare/Medicaid17
Homeland Security16
Medical/Disease Research/Clinical Labs15
Taxation/Internal Revenue Code15
Trade (domestic/foreign)2